ReviewInternational journal of nanomedicine2026
Reprogramming Metabolism and Immunity: Nanotechnology's Promise for Hepatocellular Carcinoma Precision Therapy.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of hepatocellular carcinoma (HCC) faces multiple dilemmas, including limited applicability of local therapy, easy development of resistance to targeted drugs, and low response rate to immune checkpoint inhibitors (ICIs). The core crux lies in the "metabolic reprogramming-immune suppression" vicious cycle and tumor heterogeneity. This review aims to clarify the crosstalk between metabolic reprogramming and immune suppression in HCC, and summarize the design principles of nanoplatforms for synchronous intervention in metabolism and immunity. Nanotechnology, with core advantages of precise targeting, tumor microenvironment responsiveness, and multifunctional synergy, enables targeted regulation of glucose, fatty acid, and amino acid metabolic pathways. It synergizes with ICIs and local therapies to reshape the immunosuppressive microenvironment, and the "metabolic subtype-nanocarrier" matching strategy shows promising clinical potential. Current applications face challenges in carrier performance, personalized strategies, and clinical translation. Future development focusing on carrier optimization, multi-omics-based subtype matching, and standardized evaluation systems will promote nanotechnology to evolve from "broad-spectrum regulation" to "precise adaptation", providing a core tool for overcoming HCC treatment bottlenecks and advancing precision therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.